ImmunoTherapyNews.net

Cancer immunotherapy

Xagena Mappa
Medical Meeting
XagenaNewsletter
Onco News

Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. Researchers have assessed the activity of Nivolumab ( Opdivo ), a fully human IgG4 PD-1 ...


Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation of PD-L1 and inhibition of antitumor T-cell activation is obs ...


Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activ ...


Lung cancer is the leading cause of cancer death in both men and women. PD-L1 is upregulated in non-small-cell lung carcinoma ( NSCLC ) and may be associated with a poor prognosis. MEDI4736 is a hum ...


Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation of PD-L1 and inhibition of antitumor T-cell activation is obs ...